Skip to main content

UL Hospitals Group

UL Hospitals Group is made up of 6 hospital sites in the Midwest; University Hospital Limerick, University Maternity Hospital Limerick, Ennis Hospital, Nenagh Hospital, Croom Orthopaedic Hospital and St. John's Hospital Limerick.

Read more about what we do

HSE services and information

Our hospitals

Information on the medicine, maternal and child, perioperative and diagnostic services available in our hospitals

Careers at UL Hospitals

Search for career opportunities at UL Hospitals Group

About UL Hospitals Group

Find out more about our 6 hospitals and the services they provide

UL Hospitals Quality and Patient Safety

Information on how the quality and patient safety team are working to reduce risks and improve patient experiences in our hospitals.

UL Hospitals Infection, Prevention and Control

Find out what measures are put in place to control and prevent infections in our hospitals

Information for staff

Professional development information, employee resources and supports for UL Hospitals staff

News and blogs

Dr Naro Imcha
News - 17 September 2021

Satellite COVID-19 Vaccination Clinic to open at UMHL

UL Hospitals Group is running a Satellite COVID-19 Vaccination Clinic at University Maternity Hospital Limerick from Monday September 20th to Friday September 24th, to offer vaccination for expectant mums attending the hospital and inpatients.
News -  16 September 2021
Additional Walk-In Clinics at Mid-West COVID-19 Vaccination Centres this weekend
Another series of scheduled walk-in vaccination clinics for adults, and children aged 12 and over, has been organised across the Mid-West COVID-19 Vaccination Centres in Limerick, Ennis and Nenagh this Friday, Saturday and Sunday, September 17th-19th
Lab Scientist A
News - 7 September 2021
Doors open on new €4m Molecular Laboratory at University Hospital Limerick
The recently opened Molecular Laboratory at University Hospital Limerick (UHL) has boosted the hospital’s already significant COVID-19 testing capacity, and provides the potential, post-pandemic, to increase the scope of molecular testing in infectious diseases.